Page 82 - Clinical Development News Today

Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology Holdings Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy ...

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in...

/PRNewswire/ -- PLT Health Solutions, Inc. announced that it has received an expanded license from the Natural and Non-Prescription Health Products Directorate...

A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.

Relmada Therapeutics, Inc. has announced rapid and sustained effects of an anti-depressant in patients with major depressive disorders (MDD).

WALTHAM, Mass., September 25, 2023--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc.

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of ...

An advanced wearable headband with integrated machine learning algorithms has achieved The US Food and Drug Administration’s 510(k) clearance.

Mural Health Technologies, Inc. has raised $8 million in seed funding for the growth of its Mural link platform it says is aimed at ‘modernizing the clinical trial experience for both patients and caregivers’.

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.